National Center for Tumor Diseases

InstitutionResearch output, impact & collaborations

National Center for Tumor Diseases is a research organisation in Heidelberg, DE. OpenAlex records 12,680 works and 1,761,514 citations for it. 2,508 researchers list it as their most recent affiliation.

12,680

Works

1,761,514

Citations

2,508

Researchers

79.5

Avg h-index

IDs:ROR OpenAlex

How has National Center for Tumor Diseases's publication output changed over time?

ScholarIQpublication output · 2002–2021

Output grew0% over the shown period — from 1 works in 2002 to 1 in 2021.

20022010201120162021

What are the most-cited papers on National Center for Tumor Diseases?

ScholarIQmost cited works

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr, Markus Schaich, Ulrike Schäkel, Uwe Platzbecker, Martin Wermke, Martin Bornhäuser, Markus Ritter, Andreas Neubauer, Gerhard Ehninger, Thomas Illmer

Blood. 20021,733 CitationsOPEN ACCESS

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Uwe Platzbecker, Martin Wermke, J. Radke, Uta Oelschlaegel, Franzi Seltmann, Alexander Kiani, I-M Klut, Holger Knoth, Christoph Röllig, Johannes Schetelig, Brigitte Mohr, Xina Graehlert, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede

S149476849. 2011397 CitationsOPEN ACCESS

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

Valeria Santini, António Almeida, Aristoteles Giagounidis, Stefanie Gröpper, Anna Jonášová, Norbert Vey, Ghulam J. Mufti, Rena Buckstein, Moshe Mittelman, Uwe Platzbecker, Ofer Shpilberg, Ron Ram, Consuelo del Cañizo, Norbert Gattermann, Keiya Ozawa, Alberto Risueño, Kyle J. MacBeth, Jianhua Zhong, Francis Séguy, Albert Hoenekopp, C.L. Beach, Pierre Fenaux

Journal of Clinical Oncology. 2016215 Citations

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, Lionel Adès, Aref Al‐Kali, Juan Manuel Alonso‐Domínguez, Ana Alfonso Piérola, Catherine C. Coombs, H. Joachim Deeg, Ian W. Flinn, James M. Foran, Guillermo Garcia‐Manero, Michael B. Maris, Malgorzata McMasters, Jean‐Baptiste Micol, Jaime Pérez de Oteyza, Felicitas Thol, Eunice S. Wang, Justin M. Watts, Justin Taylor, Richard M. Stone, Vikram Gourineni, Alyssa J. Marino, Huilan Yao, Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker

S149476849. 2021184 CitationsOPEN ACCESS

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

Christoph Röllig, Christian Thiede, Martin Gramatzki, Walter E. Aulitzky, H. Bodenstein, Martin Bornhäuser, Uwe Platzbecker, Reingard Stuhlmann, Ulrich S. Schuler, Silke Soucek, Michael Krämer, Brigitte Mohr, Uta Oelschlaegel, Friedrich Stölzel, Malte von Bonin, Martin Wermke, Hannes Wandt, Gerhard Ehninger, Markus Schaich, for the Study Alliance Leukemia

Blood. 2010177 CitationsOPEN ACCESS